Видео с ютуба Egfr Nsclc

Понимание лечения НМРЛ при наличии мутации EGFR

Понимание лечения НМРЛ при наличии мутации EGFR
EGFR Resisters Welcome Video: How We Can Help with EGFR+ NSCLC

EGFR Resisters Welcome Video: How We Can Help with EGFR+ NSCLC
Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC

Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
Case #2: Treating a Patient with Stage IV NSCLC with EGFR - 2025 Case Based Panel Discussions

Case #2: Treating a Patient with Stage IV NSCLC with EGFR - 2025 Case Based Panel Discussions
Что такое мутация EGFR при раке легких?

Что такое мутация EGFR при раке легких?
EGFR-Mutant Lung Cancer & Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum

EGFR-Mutant Lung Cancer & Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum
FLAURA2 outcomes by EGFR mutation subtype in advanced NSCLC

FLAURA2 outcomes by EGFR mutation subtype in advanced NSCLC
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
Сложные случаи метастатического немелкоклеточного рака легких с мутацией EGFR с доктором Эриком С...

Сложные случаи метастатического немелкоклеточного рака легких с мутацией EGFR с доктором Эриком С...
Multimodal Management of Early-Stage NSCLC: EGFR-Targeted Therapy in Perioperative Settings

Multimodal Management of Early-Stage NSCLC: EGFR-Targeted Therapy in Perioperative Settings
Dr. Piotrowska on Treatment for EGFR-Mutant NSCLC

Dr. Piotrowska on Treatment for EGFR-Mutant NSCLC
Treating Uncommon EGFR NSCLC Mutations with Osimertinib

Treating Uncommon EGFR NSCLC Mutations with Osimertinib
Safety of osimertinib plus tegavivint in first-line EGFR-mutant NSCLC

Safety of osimertinib plus tegavivint in first-line EGFR-mutant NSCLC
Sunvozertinib for NSCLC with EGFR Exon 20 - Lung Cancer OncInsights 2025-26

Sunvozertinib for NSCLC with EGFR Exon 20 - Lung Cancer OncInsights 2025-26
The challenge of treatment resistance in patients with advanced EGFR-mutated NSCLC

The challenge of treatment resistance in patients with advanced EGFR-mutated NSCLC
Therapy for EGFR Classical Mutation in NSCLC - 2025 Targeted Therapies in Lung Cancer Patient Forum

Therapy for EGFR Classical Mutation in NSCLC - 2025 Targeted Therapies in Lung Cancer Patient Forum
LAURA: osimertinib and chemoradiotherapy in stage III EGFR-m NSCLC

LAURA: osimertinib and chemoradiotherapy in stage III EGFR-m NSCLC
Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over Chemotherapy

NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over Chemotherapy